Dimensional Fund Advisors LP Sells 161,917 Shares of Integer Holdings Corporation $ITGR

Key Points

• Dimensional Fund Advisors LP reduced its stake in Integer Holdings Corporation by 9.5%, selling 161,917 shares and owning approximately 4.41% of the company by the end of the quarter.
• Integer reported $1.55 EPS for the last quarter, slightly below the consensus estimate of $1.57, but its revenue increased by 11.4% year-over-year.
• Analysts have varied ratings on Integer, with one labeling it as a Strong Buy and the consensus rating currently at Buy, with an average price target of $140.25.

Dimensional Fund Advisors LP lowered its stake in shares of Integer Holdings Corporation (NYSE:ITGR - Free Report) by 9.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,538,453 shares of the medical equipment provider's stock after selling 161,917 shares during the period. Dimensional Fund Advisors LP owned approximately 4.41% of Integer worth $181,547,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in Integer by 14.7% during the first quarter. Russell Investments Group Ltd. now owns 6,749 shares of the medical equipment provider's stock worth $796,000 after acquiring an additional 863 shares in the last quarter. Public Sector Pension Investment Board raised its position in shares of Integer by 27.4% during the first quarter. Public Sector Pension Investment Board now owns 106,382 shares of the medical equipment provider's stock worth $12,554,000 after purchasing an additional 22,847 shares during the period. Nuveen LLC bought a new position in shares of Integer during the 1st quarter valued at about $17,634,000. Aigen Investment Management LP acquired a new position in shares of Integer in the 1st quarter valued at approximately $572,000. Finally, Entropy Technologies LP bought a new stake in Integer during the 1st quarter worth approximately $719,000. 99.29% of the stock is owned by institutional investors.

Insider Activity at Integer

In other news, Director Donald J. Spence sold 14,739 shares of Integer stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total value of $1,774,280.82. Following the transaction, the director owned 18,781 shares in the company, valued at approximately $2,260,856.78. This trade represents a 43.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Martin C. Maxwell sold 8,720 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total transaction of $1,051,283.20. Following the transaction, the director owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. This represents a 28.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.16% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on ITGR. Truist Financial dropped their price objective on shares of Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a report on Friday, July 25th. Raymond James Financial cut their price target on Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a report on Friday, July 25th. Wall Street Zen upgraded Integer from a "sell" rating to a "hold" rating in a report on Monday, May 19th. Wells Fargo & Company cut their target price on Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Finally, Citigroup raised shares of Integer from a "hold" rating to a "strong-buy" rating and raised their price target for the stock from $133.00 to $140.00 in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $140.25.

Integer Stock Performance

Shares of ITGR traded down $1.5990 during midday trading on Monday, reaching $108.9810. The stock had a trading volume of 256,908 shares, compared to its average volume of 355,626. The firm has a market cap of $3.82 billion, a PE ratio of 48.01, a P/E/G ratio of 0.87 and a beta of 1.02. The firm has a 50 day simple moving average of $113.57 and a 200-day simple moving average of $118.67. Integer Holdings Corporation has a one year low of $104.93 and a one year high of $146.36. The company has a current ratio of 3.41, a quick ratio of 2.18 and a debt-to-equity ratio of 0.72.

Integer (NYSE:ITGR - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%.The firm had revenue of $476.00 million for the quarter, compared to the consensus estimate of $464.37 million. During the same quarter last year, the business posted $1.30 EPS. Integer's revenue for the quarter was up 11.4% on a year-over-year basis. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, sell-side analysts anticipate that Integer Holdings Corporation will post 6.01 EPS for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.